Novartis Faces Strict Pharmacy Oversight In $390M Deal

Law360, New York (November 20, 2015, 8:12 PM EST) -- Novartis on Friday made detailed admissions about its sales strategies with specialty pharmacies and agreed to sweeping federal oversight of its relationships with the controversial dispensers, capping off a mammoth False Claims Act case that includes a $390 million payout.

The developments were part of a kickbacks case joined in 2013 by the U.S. Department of Justice and originally filed in 2011 by former Novartis Pharmaceuticals Corp. sales manager David Kester. The whistleblower will receive 15 percent to 30 percent of the payout, which was tentatively...
To view the full article, register now.